South & Central America Influenza Vaccines Market

The South & Central America influenza vaccines market is expected to grow from US$ 497.54 million in 2022 to US$ 736.35 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

Increase in Government Support to Promote Influenza Vaccination

The governing bodies of various states and countries are supporting the promotion of vaccination through multiple activities and programs. By 2022, enough vaccines have been secured to cover all risk groups eligible for a government-funded flu vaccine through the NIP.

Below are a few more instances supporting the government support for influenza vaccination: In Oct 2021, with flu season approaching, the Provincial Government was encouraging all Newfoundlanders and Labradorians to get a flu shot in the year 2021. Starting October 25, 2021, the Regional Health Authorities (RHAs) have begun hosting free flu vaccination clinics. People can also get the vaccine through their family doctor or local pharmacy. Thus, increasing government support to promote influenza vaccination is driving the South & Central America influenza vaccines market.

Market Overview

The South & Central America influenza vaccines market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market for influenza vaccines in the region is expected to experience growth opportunities during the forecast period. The influenza vaccines market in SAM is expected to grow owing to factors such as an increase in cases of influenza in the region, surge in various research activities in the region, rise in health awareness, and an increase in healthcare expenditure by the countries of the region. 

South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Influenza Vaccines Strategic Insights

Strategic insights for the South & Central America Influenza Vaccines provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South & Central America Influenza Vaccines Report Scope

South & Central America Influenza Vaccines Regional Insights

The geographic scope of the South & Central America Influenza Vaccines refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

South & Central America Influenza Vaccines Market Segmentation

The South & Central America influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the South & Central America influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the South & Central America influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the South & Central America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the South & Central America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the South & Central America influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the South & Central America influenza vaccines market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market in 2022.

AstraZeneca; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the South & Central America influenza vaccines market.